SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is generating significant momentum following its landmark marketing approval in Japan, which has prompted analysts to raise price targets to $12. Investors are actively discussing the company's strong cash position and the upcoming U.S. clinical trial milestones, framing the stock as a compelling, undervalued opportunity in the oncology sector.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is capturing significant community attention as it secures strategic government contracts and deepens its collaboration with NVIDIA, leading investors to view it as a compelling, undervalued alternative to other quantum stocks. While some express frustration with recent price volatility and de-SPAC pressure, many are actively accumulating shares based on a long-term conviction in the companys debt-free balance sheet and its pivotal role in national security and AI integration.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings is seeing heightened volatility and intense trader interest as it joins the S&P 500 index, a move that is triggering mandatory institutional buying and significant market-making activity. The community remains sharply divided, with bulls pointing to the company's critical role in the AI optics supply chain and Nvidia's strategic investment, while bears warn of stretched valuations and risks stemming from shifting industry preferences toward copper technologies.

VanEck ETF Trust - VanEck Agribusiness ETF

VanEck Agribusiness ETF

Investors are increasingly rotating into the agricultural sector, viewing agribusiness as a defensive play that is showing signs of a structural breakout. The community is actively discussing the sector's potential to benefit from fresh inflows and long-term food demand, with many highlighting agribusiness as an undervalued, unloved trade that is finally beginning to gain momentum.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Abivax is trending due to persistent, high-profile acquisition rumors linking the French biotech to potential suitors like Eli Lilly and AstraZeneca, fueled by reports from investigative outlets and strong institutional interest. The community remains focused on the company's robust ulcerative colitis drug pipeline and the potential for a significant buyout premium, keeping trading volume high as investors monitor for official confirmation of a deal.

Invesco DB Multi-Sector Commodity Trust - Invesco DB Agriculture Fund

Invesco DB Agriculture Fund

The Invesco DB Agriculture Fund is trending as investors weigh persistent global supply chain disruptions and geopolitical instability against the potential for demand destruction in food commodities. Market participants are intensely focused on how persistent inflation, exacerbated by rising fertilizer and energy costs, will continue to impact the agriculture sector's profitability.

Starbucks Corp. engages in the production, marketing, and retailing of specialty coffee. It operates through the following segments: North America, International, and Channel Development. The North America segment focuses on the United States and Canada. The International segment is involved in China, Japan, Asia Pacific, Europe, Middle East, Africa, Latin America, and Caribbean. The Channel Development segment includes roasted whole bean and ground coffees, Seattle’s Best Coffee, and Teavana-branded single-serve products. The company was founded by Jerry Baldwin and Howard D. Schultz on November 4, 1985, and is headquartered in Seattle, WA.

Starbucks Corp.

Starbucks Corp

Starbucks is facing significant volatility as investors debate the viability of the company's turnaround plan, balancing recent traffic improvements against margin pressures and intense competition from faster, value-oriented rivals. The community remains deeply divided, with some betting on a long-term recovery under new leadership while others highlight declining brand loyalty and store closures as indicators of structural trouble.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is currently under pressure as investors weigh recent reports of large-scale layoffs against concerns over massive AI infrastructure spending and looming legal challenges. Community sentiment is sharply divided between long-term believers citing the company's valuation and dominant advertising position, and skeptical traders who view recent price action as a technical breakdown signaling further downside risk.

Global X Funds - Global X Silver Miners ETF

Global X Silver Miners ETF ($SIL) is trending as investors react to a significant silver supply-demand deficit and increasing industrial usage in sectors like AI and electric vehicles. The community is actively debating the sustainability of the recent rally, with many traders focusing on the structural decoupling of physical silver prices from paper-contract markets, while others monitor for signs of a technical correction following the rapid price appreciation.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs is gaining significant momentum as investors pivot toward defense-tech and earth-observation stocks, bolstered by its new prime contractor status under the Pentagon's SHIELD program. The community is actively discussing the company's expanding backlog, its strategic AI partnerships with industry giants like NVIDIA and Google, and its growing importance in global national security as a key source of real-time geospatial intelligence.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

GeoVax Labs (GOVX) Upgraded to Buy: What Does It Mean for the Stock?

GeoVax Labs (GOVX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Shares of GeoVax Labs Inc. (<a class="mention" data-mention="$GOVX" data-symbol-id="GOVX" href="https://stocktwits.com/symbol/GOVX" target="_blank">$GOVX</a>), SIGA Technologies Inc. (<a class="mention" data-mention="$SIGA" data-symbol-id="SIGA" href="https://stocktwits.com/symbol/SIGA" target="_blank">$SIGA</a>), and Emergent Biosolutions Inc. (<a class="mention" data-mention="$EBS" data-symbol-id="EBS" href="https://stocktwits.com/symbol/EBS" target="_blank">$EBS</a>) gained in mid-day trading on Friday after the World Health Organisation (WHO) reaffirmed that the ongoing upsurge of mpox remains a public health emergency of international concern (PHEIC).Mpox, formerly called monkeypox, is a disease similar to smallpox caused by a virus.&nbsp;“The decision was based on the rising number and continuing geographic spread of cases, operational challenges in the field, and the need to mount and sustain a cohesive response across countries and partners,” the apex health agency said in a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/WHO/status/1860015125463175343">post</a> on X (formerly Twitter).&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_22_132250_27d9a22ffc.png" alt="Screenshot 2024-11-22 132250.png">The WHO first declared mpox a PHEIC in August earlier this year because a new strain of the virus, Clade Ib, had spread to countries that had not previously reported any incidences of the disease, like Thailand and Sweden.&nbsp;Shares of GeoVax, currently working on a vaccine for mpox and smallpox, were up nearly 10% in mid-day trading on Friday. The stock has lost 47% of its value this year so far.&nbsp;<stembedurl>https://stocktwits.com/gabbs/message/593724551</stembedurl>Meanwhile, shares of SIGA Technologies Inc. (<a class="mention" data-mention="$SIGA" data-symbol-id="SIGA" href="https://stocktwits.com/symbol/SIGA" target="_blank">$SIGA</a>), developing an investigational drug for treating mpox called tecovirimat (TPOXX),&nbsp; jumped 2.5% after the news.&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_22_134247_8c8f14c041.png" alt="Screenshot 2024-11-22 134247.png">Retail sentiment around the stock improved to ‘bullish’ (60/100) from ‘neutral’ a day ago.&nbsp;SIGA Technologies’ shares have gained 11% this year so far.There was less movement around Emergent Biosolutions Inc. (<a class="mention" data-mention="$EBS" data-symbol-id="EBS" href="https://stocktwits.com/symbol/EBS" target="_blank">$EBS</a>), also working on a vaccine for mpox, which saw a marginal uptick of 0.6% in mid-day trading on Friday.&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_22_134547_d67811671e.png" alt="Screenshot 2024-11-22 134547.png">Retail sentiment around the stock remained in the ‘neutral’ zone with no significant change in chatter.&nbsp;Emergent Biosolutions’ vaccine, approved for smallpox, has also been used as a mpox shot, but the U.S. Food and Drug Administration is yet to approve its application for use against the virus.<stembedurl>https://stocktwits.com/WinstonSmith33/message/593679534</stembedurl>In 2022, the company acquired the rights to a smallpox treatment called Tembexa, which was developed by Chimerix Inc. ($CMRX), for up to $337.5 million plus royalties.Chimerix was up around 0.6% as well during mid-day trading.&nbsp;For updates and corrections email newsroom[at]stocktwits[dot]com.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/agrify-stock-doubles-to-hit-over-1-year-high-after-25-9-m-placement-but-retail-wary-of-short-covering-rally/cJIdTKHRg3">Agrify Stock Doubles To Hit Over 1-Year High After $25.9M Placement, But Retail Wary Of Short-Covering Rally</a>

Mpox, formerly called monkeypox, is a disease similar to smallpox caused by a virus. | Source: Pexels

GeoVax, SIGA Jump After WHO Extends Mpox Public Emergency Status: Here’s What Retail Thinks

Emergent Biosolutions and Chimerix also saw marginal gains after the announcement. 

Equity

Emergent Biosolutions and Chimerix also saw marginal gains after the announcement. 


The recent mpox outbreak has caused some worries, but has directed market attention toward U.S. vaccine and drug developers. Here's a breakdown of American pharma contenders grabbing the most retail investor interest over the past week:GeoVax Labs Inc (GOVX): Having risen nearly 230% in a week, GOVX is the runaway leader in terms of gains. During the same period, the number of Stocktwits followers of the stock jumped 18% and message volume soared 5,216%.However, the pre-market price tumbled on Tuesday after a share dilution agreement. While Geovax currently has no marketed products, it <a href="https://stocktwits.com/news/markets/equity/geovax-labs-stock-soars-as-mpox-worries-grow/c7vV0nJRTF">has published research</a> suggesting its vaccines could combat mpox and expanded its license to include the virus in December 2023.Additionally, brokerage Roth MKM reportedly believes Geovax's GEO-MVA vaccine could be the first product to market for mpox.Emergent Biosolutions Inc (EBS): With 77% weekly gains, EBS has seen its Stocktwits sentiment shift to ‘extremely bullish’ (92/100) with high message volume, after the company responded to the WHO's call for vaccine manufacturers to submit its product for Emergency Use Listing (EUL) consideration.<figure class="image"><img style="aspect-ratio:1310/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/EBS_sentiment_and_message_volume_Aug_20_premarket_0a11af5751.png" alt="EBS sentiment and message volume Aug 20 premarket.png" width="1310" height="316"><figcaption>EBS sentiment and message volume Aug 20 premarket</figcaption></figure>“As the WHO has declared, the mpox outbreak is a public health emergency of international concern, and Emergent is ready to scale up response efforts and partner with U.S. and global public health leaders," said Emergent CEO Joe Papa.<stembedurl>https://stocktwits.com/money1800/message/583452669</stembedurl>&nbsp;Emergent's existing smallpox vaccine is used off-label for mpox, but a formal FDA approval for mpox use is pending.SIGA Technologies Inc (SIGA): SIGA is up 14% over the week, but has lost some momentum after its mpox drug failed to meet a primary study goal.However, the company maintains the drug is available for use under compassionate use protocols. Retail sentiment remains ‘bullish’ (68/100) on Stocktwits, albeit lower than last week.<figure class="image"><img style="aspect-ratio:1310/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SIGA_sentiment_and_message_volume_Aug_20_premarket_d9adbdd32b.png" alt="SIGA sentiment and message volume Aug 20 premarket.png" width="1310" height="316"><figcaption>SIGA sentiment and message volume Aug 20 premarket</figcaption></figure>Tonix Pharmaceuticals Holding Corp (TNXP): Having declined 14% over the past week, TNXP has reiterated its commitment to develop its mpox vaccine, TNX-801.However, a Q2 earnings miss and user pessimism on Stocktwits have driven sentiment into "extremely bearish" (12/100) territory.<figure class="image"><img style="aspect-ratio:1310/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/TNXP_sentiment_and_message_volume_Aug_20_premarket_1856547dea.png" alt="TNXP sentiment and message volume Aug 20 premarket.png" width="1310" height="316"><figcaption>TNXP sentiment and message volume Aug 20 premarket</figcaption></figure>

Colorized transmission electron micrograph of mpox virus particles

Emergent, Geovax, Tonix, Siga: Which Mpox-Linked Stocks Are Retail Investors Most Excited About?

Retail investors are ‘extremely bullish’ on Emergent Biosolutions as it expressed readiness to scale up response efforts for the WHO health emergency.

Among the four U.S.-listed pharma stocks, retail investors are ‘extremely bullish’ on Emergent Biosolutions as it expressed readiness to scale up response efforts for the WHO health emergency.

<h1>These Three Stocks are Experiencing an Outbreak– Or a Breakout Depending How you Look at it</h1><h3>Monkeypox Outbreak Fuels Surge in Related Biopharma Stocks</h3>The recent resurgence of monkeypox has sparked widespread concern and reignited the market's interest in companies working to combat viral diseases. As the outbreak spreads, parallels to the COVID-19 pandemic are being drawn in both the media and financial markets. During the COVID-19 crisis, pharmaceutical companies that developed vaccines, treatments, and diagnostics experienced unprecedented growth, with investors flocking to these stocks in search of gains. Now, as the world faces another potential health emergency, a new set of companies is stepping into the spotlight.The global health community and investors alike are keeping a close eye on monkeypox, a disease caused by the monkeypox virus, which shares similarities with smallpox. While the outbreaks have been sporadic and relatively contained in the past, recent concerns have shifted focus toward vaccine and treatment development. The monkeypox market, although smaller in scope than COVID-19, holds significant potential. The World Health Organization and public health bodies are calling for increased awareness, testing, and vaccination. As a result, companies developing monkeypox-related therapies and vaccines are seeing their stock prices soar.Three such companies—GeoVax Labs, Tonix Pharmaceuticals, and Chimerix—are garnering substantial interest. All three have ties to the smallpox market, which, in turn, gives them relevance in the monkeypox conversation. Below is a review of these companies, their roles in combating the outbreak, and their stock performance over the short, medium, and long term.<a href="https://wealthyvc.com/featured/tiny-healthcare-stock-with-35-million-market-cap-becomes-major-player-overnight-in-rapidly-growing-1-billion-market/">This Tiny Healthcare Stock With $35M Market Cap Becomes Major Player Overnight in Rapidly Growing $1 Billion Blood Clot Market</a><a href="https://stocktwits.com/symbol/GOVX">GeoVax Labs (NASDAQ: GOVX)</a>GeoVax Labs has emerged as one of the frontrunners in the monkeypox vaccine race. Based in Georgia, this clinical-stage biotechnology company specializes in vaccines that leverage its proprietary Modified Vaccinia Ankara Virus-Like Particle (MVA-VLP) platform. The company has been developing vaccines for various infectious diseases, including smallpox, Ebola, and Lassa fever. However, with the recent monkeypox outbreak, GeoVax's focus on viral hemorrhagic fevers and poxvirus diseases has become particularly relevant.GeoVax's stock soared as concerns around monkeypox escalated, with investors seeing potential in its MVA-based vaccine technology. Its smallpox vaccine is designed to offer cross-protection against monkeypox due to the close relation between the two viruses. This has made GeoVax a significant player in the biopharma space, as public health agencies explore all options for controlling the spread of the virus.<ul><li>1-Day Return: +33%</li><li>1-Month Return: +234%</li><li>1-Year Return: +21%</li></ul>GeoVax shares have experienced strong upward momentum over the past month, driven by mounting concerns over monkeypox. Over the past year, the stock has gained substantial value as the company has positioned itself as a leader in the viral vaccine space.<a href="https://stocktwits.com/symbol/TNXP">Tonix Pharmaceuticals (NASDAQ: TNXP)</a><a href="https://stocktwits.com/symbol/TNXP"><img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_08_19_at_9_53_43_PM_2ed6d91698.png" alt="Screenshot 2024-08-19 at 9.53.43 PM.png"></a>Tonix Pharmaceuticals, another biotech firm in the spotlight, is developing live virus vaccines that may offer protection against monkeypox and other orthopoxvirus diseases. Based in New Jersey, Tonix has focused on immunology, chronic diseases, and rare infectious diseases. One of its notable projects is its live virus vaccine candidate, TNX-801, designed to protect against both smallpox and monkeypox.A recent Benzinga article highlighted the company’s preclinical results, which demonstrated long-term immunity and protection against these viruses. Tonix’s TNX-801 is based on a horsepox viral platform, which is closely related to smallpox and monkeypox. The company is working on creating a robust, durable immune response that can withstand mutations and future outbreaks. What makes Tonix attractive is the potential for TNX-801 to be used as a preventive measure in populations at high risk of contracting monkeypox.<ul><li>1-Day Return: +40%</li><li>1-Month Return: +12%</li><li>1-Year Return: -98%</li></ul>Tonix Pharmaceuticals has seen a notable rise in its stock price over the past month, as interest in its vaccine candidate has intensified. However, the stock’s performance over the past year reflects the inherent volatility in biotech investing, with a significant drop amid broader market conditions and uncertainty in the clinical trial space.<a href="https://stocktwits.com/symbol/CMRX">Chimerix, Inc. (NASDAQ: CMRX)</a><a href="https://stocktwits.com/symbol/CMRX"><img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_08_19_at_9_54_50_PM_c72f46e0e8.png" alt="Screenshot 2024-08-19 at 9.54.50 PM.png"></a>Chimerix, Inc., a biotechnology company based in North Carolina, is another name linked to the monkeypox outbreak. While the company gained attention for its smallpox drug, Tembexa, the renewed interest in orthopoxviruses like monkeypox has brought Chimerix back into the conversation. Tembexa (brincidofovir) is an FDA-approved treatment for smallpox, which gives Chimerix an edge as governments explore stockpiling options for poxvirus diseases.Though Chimerix has not explicitly developed a monkeypox treatment, the parallels between smallpox and monkeypox suggest that Tembexa could play a role in mitigating the effects of the outbreak. The drug's broad-spectrum antiviral activity makes it a candidate for off-label use in monkeypox cases. In a market where few treatments exist, Chimerix’s existing FDA approval for Tembexa may provide a quicker pathway for emergency use if the monkeypox crisis intensifies.<ul><li>1-Day Return: +5%</li><li>1-Month Return: +20%</li><li>1-Year Return: +14%</li></ul>Chimerix’s stock has seen a short-term bump as investors reevaluate its smallpox drug in light of the monkeypox outbreak. However, much like Tonix, the stock’s performance over the past year has been challenging, marked by sell-offs and investor uncertainty around the company’s long-term prospects.ConclusionAs monkeypox continues to spread, the market is once again turning to biopharmaceutical companies for solutions.&nbsp;GeoVax Labs,&nbsp;Tonix Pharmaceuticals, and&nbsp;Chimerix Inc. are at the forefront of efforts to address this public health crisis, each leveraging its expertise in smallpox and viral disease research. While the global market for monkeypox treatments is still emerging, these companies are well-positioned to capture the growing demand for vaccines and antiviral treatments.Investors should keep a close eye on clinical developments, regulatory approvals, and government stockpiling programs, as these will be key drivers of stock performance in the coming months. Like the COVID-19 pandemic, the monkeypox outbreak has the potential to create significant winners in the biotech sector. However, as always with biopharma stocks, the risks are high, and careful due diligence is necessary before jumping into this volatile space.&nbsp;Read Next:&nbsp;<a href="https://wealthyvc.com/featured/tiny-healthcare-stock-with-35-million-market-cap-becomes-major-player-overnight-in-rapidly-growing-1-billion-market/">This Tiny Healthcare Stock With $35M Market Cap Becomes Major Player Overnight in Rapidly Growing $1 Billion Blood Clot Market</a><a href="https://www.facebook.com/groups/WealthyVC">Join the Discussion in the WVC Facebook Investor Group</a>Have a Stock Tip or New&nbsp; Story Suggestion? Email us at&nbsp;<a href="mailto:Invest@WealthyVC.com">Invest@WealthyVC.com</a>This article is from an unpaid external contributor. It does not represent Stocktwits reporting or views and has not been edited for content or accuracy.&nbsp;&nbsp;

These Three Stocks are Experiencing an Outbreak– Or a Breakout Depending How you Look at it

GeoVax Labs, Tonix Pharmaceuticals, and Chimerix see stock surge amid monkeypox outbreak, leveraging their expertise in viral diseases and smallpox-related vaccines.

Monkeypox Outbreak Boosts These Biopharma Stocks

The monkeypox outbreak has boosted stocks of GeoVax Labs, Tonix Pharmaceuticals, and Chimerix. These companies are developing vaccines and treatments related to smallpox and viral diseases, positioning them as key players in addressing this health crisis.

<a href="https://stocktwits.com/symbol/GOVX">Geovax Labs</a> (GOVX) is currently the hottest stock on Stocktwits, with shares surging over 56% in pre-market trading on Monday. Notably, the rally follows a near 111% rise in the stock price on Friday.The company’s new retail followers on Stocktwits jumped by 9% and message volume exploded by over 8,300% in the past week.This meteoric rise is largely attributed to the increased focus on mpox following the World Health Organization's declaration of a global health emergency. The European Centre for Disease Prevention and Control (ECDC) has also issued a new risk assessment, further fueling concerns about the disease.Geovax has positioned itself as a potential key player in the fight against mpox. The company previously published research suggesting its vaccines could help prevent the disease and expanded its commercial license to include mpox and smallpox in December 2023.Brokerage Roth MKM reportedly believes Geovax's GEO-MVA vaccine could be the first product to market for mpox.In contrast, Siga Technologies (SIGA), an earlier frontrunner in the mpox treatment space,saw its stock decline over 2% in Monday’s premarket session. This follows disappointing top-line results from a trial testing its TPOXX drug for mpox. While the drug showed some clinical benefits, it failed to meet its primary endpoint.Interestingly, despite the setback, retail investor sentiment for SIGA on Stocktwits has surprisingly flipped to ‘extremely bullish’ territory (93/100), suggesting hopes for a turnaround.<figure class="image"><img style="aspect-ratio:1320/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SIGA_sentiment_and_message_volume_Aug_19_premarket_25843ab158.png" alt="SIGA sentiment and message volume Aug 19 premarket.png" width="1320" height="318"><figcaption>SIGA sentiment and message volume Aug 19 premarket</figcaption></figure>While both companies are in the spotlight due to the mpox outbreak, Geovax has clearly captured more retail investor attention for now.<stembedurl>https://stocktwits.com/RWROCKPORT/message/583340518</stembedurl>&nbsp;Year-to-date, GOVX has gained over 27%, while SIGA is up 80%.

Geovax previously published research suggesting its vaccines could help prevent mpox.

Geovax Labs Stock Keeps Soaring, Grabs Most Retail Attention As Mpox Concerns Grow

With another health agency issuing alerts about the rapidly spreading disease similar to smallpox, GOVX stock has seen its stock surge by more than 270% in the past week.

With another health agency issuing alerts about the rapidly spreading disease similar to smallpox, GOVX has seen its stock surge by more than 270% in the past week.


Siga Technologies (SIGA), a pharmaceutical company specializing in treatments for smallpox and related diseases, saw its stock surge nearly 27% on Wednesday as the World Health Organization (WHO) declared Mpox a public health emergency of international concern, leading to a spike in retail investor interest.Following the WHO announcement, SIGA became the stock that added the most new watchers on Stocktwits in the last 24 hours. Retail investor sentiment turned ‘extremely bullish’ with a score of 95 out of 100, while message volume peaked at its highest level this year (97/100).<figure class="image"><a href="https://stocktwits.com/symbol/SIGA"><img style="aspect-ratio:1320/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SIGA_sentiment_and_message_volume_Aug_15_premarket_5de8758c81.png" alt="SIGA sentiment and message volume Aug 15 premarket.png" width="1320" height="318"></a><figcaption>SIGA sentiment and message volume Aug 15 premarket</figcaption></figure>The rise in Mpox cases in Africa prompted the WHO's declaration, sparking renewed interest in pharmaceutical stocks linked to the disease. SIGA is particularly well-positioned as its antiviral drug, TPOXX (tecovirimat), has been used to treat Mpox, especially in severe cases.Last month, the company's stock received a boost after the U.S. Department of Health and Human Services exercised a $113 million contract option for oral TPOXX treatments.<stembedurl>https://stocktwits.com/goodupsidestockfinder/message/582972463</stembedurl>Adding to the optimism, SIGA reported strong Q2 financial results earlier this month, swinging to a profit with revenue surging from $5.88 million to $21.81 million.<a href="https://stocktwits.com/symbol/GOVX">GeoVax Labs</a> (GOVX), another pharmaceutical company, saw its stock price rise 30% on Wednesday following the WHO announcement.In December 2023, GOVX expanded its commercial license to include Mpox and smallpox through an agreement with the National Institute of Allergy and Infectious Diseases. This ticker is also garnering a lot of retail attention on the WHO’s announcement.<stembedurl>https://stocktwits.com/GOVXBULL/message/582978461</stembedurl>

SIGA's antiviral drug, TPOXX (tecovirimat), has been used to treat Mpox, especially in severe cases. Representative image via Vecteezy

Siga Technologies Stock Adds Most New Retail Watchers After WHO Declares Mpox Health Emergency

Retail investor sentiment on Stocktwits turned 'extremely bullish' with message volume reaching its highest level this year.

GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. It focuses on preventive vaccines against hemorrhagic fever viruses such as Ebola, Sudan, Marburg, and Lassa fever, the Zika virus and malaria, and human immunodeficiency virus, as well as immunotherapies for solid tumor cancers. The company was founded in June 1988 and is headquartered in Smyrna, GA.

Current Price	$1.47
Prev Close	$1.43
Open	$1.47
Dividend Yield	0.00%
50-Day Moving Average	$2.31
Beta	1.41
Avg. Volume	145,959.43
PE Ratio	-0.03

52-Week High	$35.25
52-Week Low	$1.26
Market Capitalization	$3.27M
EPS (Annual)	-$120.46
Price to Book	0.36
Revenue Per Employee	$232,622.12

GOVX
Geovax Labs Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GOVX News

GOVXGeovax Labs Inc